Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation

Condition(s) studied

Investigational drug(s) / intervention(s)

Feedback-controlled temperature device: If core body temperature exceeds 37.7°C a feedback controlled-device will be used and set at 37.5°C.

High MAP: A MAP target of \>85mmHg will be used. Vasopressors will be titrated to this target during 36h.

Deep sedation: Deep sedation for at least 36h

Fever control without a device: Management of fever in the ICU without a device

Low MAP: A MAP target of \>65mmHg will be used. Vasopressors will be titrated to this target during 36h.

Minimal sedation: A strategy of minimal sedation in the ICU, used only as needed to facilitate transport, imaging and invasive procedures.

Study summary

The STEPCARE-trial is a 2x2x2 randomised trial studying patients who have been resuscitated from cardiac arrest and who are comatose. It will include three different interventions focusing on sedation targets, temperature targets and mean arterial pressure targets.

Eligibility

Primary outcome measure(s)

• Mortality — 6 months
  Landmark mortality at follow-up performed at 6 months

Trial sites (56)

+ 16 more sites — see the full list on the official registry below.

More Region Skane trials in Belgium

Other trials for the same condition